EGFR and melanoma: To test whether this finding might be of translational relevance and ERBB inhibition might sensitize MAPKi-resistant melanoma cells to Vemurafenib, we treated melanoma cell lines with acquired MAPKi resistance and different MITF/AXL phenotypes with a combination of the pan-ERBB inhibitor Afatinib (Fig. 6h) and Vemurafenib, and observed a re-sensitization effect for the combination treatment in MITFlow/AXLhigh resistant melanoma cells with high RTK activity.